Atherosclerotic change at one year after implantation of Endeavor zotarolimus-eluting stent vs. everolimus-eluting stent

18Citations
Citations of this article
15Readers
Mendeley users who have this article in their library.

Abstract

Background: Atherosclerosis progression is thought to be one of the mechanisms of late stent failure. Atherosclerosis progression is detected as yellow plaque formation on angioscopy. Cypher sirolimus-eluting stent has been reported to accelerate atherosclerosis progression, but the influence of Endeavor zotarolimus-eluting stent (Endeavor- ZES) or Xience everolimus-eluting stent (Xience-EES) on atherosclerosis has not been clarified. Therefore, we examined the serial changes in extent of atherosclerosis after the implantation of Endeavor-ZES or Xience-EES. Methods and Results: Consecutive patients who received implantation of Endeavor-ZES (n=25) or Xience-EES (n=30) at de novo lesion of native coronary artery and who had successful angioscopy immediately after stent implantation (baseline) and at 1-year follow-up were included in the study. Change in the maximum yellow color grade (grade 0-3) of the stented segment from baseline to follow-up was examined and was compared between Endeavor- ZES and Xience-EES. The maximum yellow color grade decreased significantly from baseline to follow-up in Endeavor-ZES (1.6±1.1 vs. 0.4±0.8, P<0.001), but it did not change in Xience-EES (1.7±1.0 vs. 1.4±0.7, P=0.23). Although the maximum yellow color grade was not different between Endeavor-ZES and Xience-EES at baseline (P=0.72), it was significantly lower in Endeavor-ZES than in Xience-EES at follow-up (P<0.001). Conclusions: Atherosclerosis evaluated by yellow color of the plaque was significantly reduced at 1 year after Endeavor-ZES implantation, but was not changed after Xience-EES implantation.

References Powered by Scopus

Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study

1617Citations
N/AReaders
Get full text

Pathological correlates of late drug-eluting stent thrombosis: Strut coverage as a marker of endothelialization

1213Citations
N/AReaders
Get full text

One-Year Clinical Results with the Slow-Release, Polymer-Based, Paclitaxel-Eluting TAXUS Stent: The TAXUS-IV Trial

763Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Mechanistic evaluation of long-term in-stent restenosis based on models of tissue damage and growth

32Citations
N/AReaders
Get full text

Five-year clinical efficacy and safety of contemporary thin-strut biodegradable polymer versus durable polymer drug-eluting stents: a systematic review and meta-analysis of 9 randomized controlled trials

24Citations
N/AReaders
Get full text

Role of mammalian target of rapamycin in atherosclerosis

16Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Akazawa, Y., Matsuo, K., Ueda, Y., Nishio, M., Hirata, A., Asai, M., … Kodama, K. (2014). Atherosclerotic change at one year after implantation of Endeavor zotarolimus-eluting stent vs. everolimus-eluting stent. Circulation Journal, 78(6), 1428–1436. https://doi.org/10.1253/circj.CJ-14-0085

Readers over time

‘14‘16‘17‘18‘19‘20‘2502468

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 3

38%

Professor / Associate Prof. 2

25%

Researcher 2

25%

Lecturer / Post doc 1

13%

Readers' Discipline

Tooltip

Medicine and Dentistry 8

73%

Pharmacology, Toxicology and Pharmaceut... 1

9%

Social Sciences 1

9%

Engineering 1

9%

Save time finding and organizing research with Mendeley

Sign up for free
0